2076975 2077203
최종편집 2024-06-15 22:14 (토)
Benefits for AjovyㆍLucen-BSㆍAmeliebou are granted, 25% cut in Revlimid
상태바
Benefits for AjovyㆍLucen-BSㆍAmeliebou are granted, 25% cut in Revlimid
  • Hyeokgi Lee, Newsmp
  • 승인 2022.12.29 11:56
  • 댓글 0
이 기사를 공유합니다

Amended the pharmaceutical benefit list and the table of the upper limit of benefits
Chong Kun Dang Pharmaceutical’s four-drug Nuvorozet newly entered

[Newsmp] Migraine treatment Ajovy (Teva-Handok), Lucen-BS (Chong Kun Dang Pharmaceutical), a biosimilar referencing Ranibizumab (original product: Lucentis) and Ameliebou (Samsung Bioepis) will enter the pharmaceutical benefit list for the new year.

Three products of Chong Kun Dang Pharmaceutical’s Nuvorozet, four-drug combination treatments for high blood pressure-hyperlipidemia, will also be added to the list. Among the existing items, the upper limit of benefits for Repatha (Amgen), Entresto (Novartis) and Revlimid (Celgene) is going to be lowered.

The Ministry of Health and Welfare amended the pharmaceutical benefit list and the table of the upper limit of benefits and issued it on the 26th.

According to the notification, two dosage forms of Ajovy, a prefilled syringe Inj. and autoinjector Inj., will be registered on the benefit list.

Lucen-BS’s maximum amount is set at KRW 300,000 per 0.3ml/vial and Ameliebou at KRW 463,773 per 0.23ml/vial.

Chong Kun Dang Pharmaceutical’s amlodipine/telmisartan/rosuvastatin/ezetimibe four-drug Nuvorozet is set at KRW 1,490 for 40/2.5/5/10mg, KRW 1,610 for 40/5/5/10mg and KRW 1,940 for 40/5/10/10mg.

HK inno.N’s Potassium Competitive Acid Blocker (P-CAB) K-CAB is added with an upper limit of KRW 867 for 25mg for maintenance therapy after treatment of erosive gastroesophageal reflux disease.

Among the existing drugs, Revlimid’s 5mg and 10mg doses are reduced by 25%, and Entresto’s three doses of 50, 100 and 250mg by 6.2% from KRW 1,920 to KRW 1,792.

Janssen’s two dosage forms of Darzalex (5ml, 20ml) and Amgen’s Repatha will also be cut by 2%, Elyson Pharm.’s Eritibe Tab. by 53.1%, PharmGen Science’s Pari BM by 15%, Boryung Pharmaceutical’s Fulvet by 2.2% and Roche’s Gazyva by 3.5%.

On the other hand, the upper limit of two products of Samnam Acetaminophen (0.3g, 500mg) is raised by 15.8%, Green Pharmaceutical’s Green Hexidine Oral Rinse 0.12% by 28.2% and Hanlim Pharmaceutical’s Urinon by 21.8%.

For Hanmi Pharmaceutical’s Vildagle Tab. 50mg and Kyongbo Pharmaceutical’s Vilda Tab. 50mg, which were scheduled to have a lower upper limit of benefits, the existing upper limit will be maintained and will be reduced to KRW 240 per tablet on 9 Jan. 2025.

 


댓글삭제
삭제한 댓글은 다시 복구할 수 없습니다.
그래도 삭제하시겠습니까?
댓글 0
댓글쓰기
계정을 선택하시면 로그인·계정인증을 통해
댓글을 남기실 수 있습니다.